The global threat of antimicrobial resistance: Science for intervention

New Microbes and New Infections

Volumn 6, Issue , 2015, Pages 22-29

  Roca, I ^a   Akova, M ^b,y   Baquero, F ^c   Carlet, J ^d,e   Cavaleri, M ^f   Coenen, S ^g   Cohen, J ^h   Findlay, D ⁱ   Gyssens, I ^j   Heure, O E ^k   Kahlmeter, G ^l,y,z   Kruse, H ^m   Laxminarayan, R ^n,o   Liebana E ^p   Lopez Cerero L ^q   MacGowan, A ^r,z   Martins, M ^s   Rodriguez Bano J ^q,y   Rolain, J M ^t   Segovia, C ^u   Sigauque, B ^v   Taconelli, E ^w,y   Wellington, E ^x   Vila, J ^a,y   more..

^a CENTRE FOR RESEARCH IN ENVIRONMENTAL EPIDEMIOLOGY CREAL   (Spain)

^b HACETTEPE UNIVERSITY   (Turkey)

^c HOSPITAL RAMÓN Y CAJAL   (Spain)

^d SAINT JOSEPH HOSPITAL   (France)

^e World Alliance Against Antibiotic Resistance (WAAAR)   (France)

^f EUROPEAN MEDICINES AGENCY   (United Kingdom)

^g UNIVERSITY OF ANTWERP   (Belgium)

^h BRIGHTON AND SUSSEX MEDICAL SCHOOL   (United Kingdom)

ⁱ GLAXOSMITHKLINE   (United Kingdom)

^j RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^k EUROPEAN CENTRE FOR DISEASE PREVENTION AND CONTROL ECDC   (Sweden)

^l CENTRAL HOSPITAL   (Sweden)

^m WHO REGIONAL OFFICE FOR EUROPE   (Denmark)

ⁿ Center for Disease Dynamics Economics and Policy   (United States)

^o PRINCETON UNIVERSITY   (United States)

^p EUROPEAN FOOD SAFETY AUTHORITY   (Italy)

^q HOSPITAL UNIVERSITARIO VIRGEN MACARENA   (Spain)

^r SOUTHMEAD HOSPITAL   (United Kingdom)

^s UNIVERSITY COLLEGE DUBLIN   (Ireland)

^t AIX MARSEILLE UNIVERSITÉ   (France)

^u INSTITUTO DE SALUD CARLOS III   (Spain)

^v INSTITUTO NACIONAL DE SAÚDE   (Mozambique)

^w UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^x UNIVERSITY OF WARWICK   (United Kingdom)

^y International Association for the Study of Attention   (Switzerland)

^z EUCAST Steering Committee   (Sweden)

more..

Author keywords

Antibiotic consumption; Antibiotic resistance; Antibiotic stewardship; Antibiotics as growth promoters; Drug discovery; Infection control measures; Multidrug resistant bacteria; Self medication; Surveillance; Wastewater treatment plants

Indexed keywords

CARBAPENEM DERIVATIVE; CEPHALOSPORIN DERIVATIVE; QUINOLONE;

ANTIBIOTIC RESISTANCE; COMMUNITY; DRUG RESEARCH; DRUG USE; EDUCATION PROGRAM; ENVIRONMENT; EVOLUTIONARY DEVELOPMENTAL BIOLOGY; FOOD CHAIN; HEALTH CARE FACILITY; HEALTH CARE SYSTEM; HEALTH PROGRAM; HUMAN; NONHUMAN; PRACTICE GUIDELINE; PRESCRIPTION; PRIORITY JOURNAL; REVIEW; WASTE WATER MANAGEMENT;

ANIMALIA; BACTERIA (MICROORGANISMS);

EID: 84930202457     PISSN: 20522975     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nmni.2015.02.007     Document Type: Review

References (40)

1. Marshall B.M., Levy S.B. Food animals and antimicrobials: impacts on human health. Clin Microbiol Rev 2011, 24:718-733.
2. Liebana E., Carattoli A., Coque T.M., Hasman H., Magiorakos A.P., Mevius D., et al. Public health risks of enterobacterial isolates producing extended-spectrum beta-lactamases or AmpC beta-lactamases in food and food-producing animals: an EU perspective of epidemiology, analytical methods, risk factors, and control options. Clin Infect Dis 2013, 56:1030-1037.
3. European Centre for Disease Prevention and Control (ECDC), European Food Safety Authority (EFSA), European Medicines Agency (EMEA) Joint opinion on antimicrobial resistance (AMR) focused on zoonotic infections 2009, Available at:, [accessed 8.5.15]. http://www.efsa.europa.eu/en/scdocs/doc/1372.pdf.
4. World Health Organization WHO list of critically important antimicrobials (CIA), 3rd revision 2011, Available at:, [accessed 8.5.15]. http://www.who.int/foodsafety/publications/antimicrobials-third/en/.
5. Colpan A., Johnston B., Porter S., Clabots C., Anway R., Thao L., et al. Escherichia coli sequence type 131 (ST131) subclone H30 as an emergent multidrug-resistant pathogen among US veterans. Clin Infect Dis 2013, 57:1256-1265.
6. Bruyndonckx R., Hens N., Aerts M., Goossens H., Molenberghs G., Coenen S. Measuring trends of outpatient antibiotic use in Europe: jointly modelling longitudinal data in defined daily doses and packages. JAntimicrob Chemother 2014, 69:1981-1986.
7. European Centre for Disease Prevention and Control (ECDC), European Antimicrobial Surveillance Network (EARS-NET) Technical report 2013, Antimicrobial resistance surveillance in Europe, 2012, Available at:, [accessed 8.5.15]. http://ecdc.europa.eu/en/publications/Publications/antimicrobial-resistance-surveillance-europe-2012.pdf.
8. Voulgari E., Poulou A., Koumaki V., Tsakris A. Carbapenemase-producing Enterobacteriaceae: now that the storm is finally here, how will timely detection help us fight back?. Future Microbiol 2013, 8:27-39.
9. Coenen S., Gielen B., Blommaert A., Beutels P., Hens N., Goossens H. Appropriate international measures for outpatient antibiotic prescribing and consumption: recommendations from a national data comparison of different measures. JAntimicrob Chemother 2014, 69:529-534.
10. Laxminarayan R., Klugman K.P. Communicating trends in resistance using a drug resistance index. BMJ Open 2011, 1:e000135.
11. Spellberg B., Guidos R., Gilbert D., Bradley J., Boucher H.W., Scheld W.M., et al. The epidemic of antibiotic-resistant infections: a call to action for the medical community from the Infectious Diseases Society of America. Clin Infect Dis 2008, 46:155-164.
12. Coenen S., Francis N., Kelly M., Hood K., Nuttall J., Little P., et al. Are patient views about antibiotics related to clinician perceptions, management and outcome? A multi-country study in outpatients with acute cough. PLoS One 2013, 8:e76691.
13. Spellberg B., Blaser M., Guidos R.J., Boucher H.W., Bradley J.S., Eisenstein B.I., et al. Combating antimicrobial resistance: policy recommendations to save lives. Clin Infect Dis 2011, 52(Suppl.5):S397-S428.
14. Laxminarayan R., Heymann D.L. Challenges of drug resistance in the developing world. BMJ 2012, 344:e1567.
15. Morgan D.J., Okeke I.N., Laxminarayan R., Perencevich E.N., Weisenberg S. Non-prescription antimicrobial use worldwide: a systematic review. Lancet Infect Dis 2011, 11:692-701.
16. Wellington E.M., Boxall A.B., Cross P., Feil E.J., Gaze W.H., Hawkey P.M., et al. The role of the natural environment in the emergence of antibiotic resistance in Gram-negative bacteria. Lancet Infect Dis 2013, 13:155-165.
17. Finley R.L., Collignon P., Larsson D.G., McEwen S.A., Li X.Z., Gaze W.H., et al. The scourge of antibiotic resistance: the important role of the environment. Clin Infect Dis 2013, 57:704-710.
18. Heuer O.E., Kruse H., Grave K., Collignon P., Karunasagar I., Angulo F.J. Human health consequences of use of antimicrobial agents in aquaculture. Clin Infect Dis 2009, 49:1248-1253.
19. Pruden A., Larsson D.G., Amezquita A., Collignon P., Brandt K.K., Graham D.W., et al. Management options for reducing the release of antibiotics and antibiotic resistance genes to the environment. Environ Health Perspect 2013, 121:878-885.
20. Tacconelli E., Cataldo M.A., Dancer S.J., De Angelis G., Falcone M., Frank U., et al. ESCMID guidelines for the management of the infection control measures to reduce transmission of multidrug-resistant Gram-negative bacteria in hospitalized patients. Clin Microbiol Infect 2014, 20(Suppl.1):1-55.
21. Berger A., Edelsberg J., Oster G., Huang X., Weber D.J. Patterns of initial antibiotic therapy for community-acquired pneumonia in US hospitals, 2000 to 2009. Am J Med Sci 2014, 347:347-356.
22. Blommaert A., Marais C., Hens N., Coenen S., Muller A., Goossens H., et al. Determinants of between-country differences in ambulatory antibiotic use and antibiotic resistance in Europe: a longitudinal observational study. JAntimicrob Chemother 2014, 69:535-547.
23. Cisneros J.M., Neth O., Gil-Navarro M.V., Lepe J.A., Jimenez-Parrilla F., Cordero E., et al. Global impact of an educational antimicrobial stewardship programme on prescribing practice in a tertiary hospital centre. Clin Microbiol Infect 2014, 20:82-88.
24. Gyssens I.C., Kern W.V., Livermore D.M. The role of antibiotic stewardship in limiting antibacterial resistance among hematology patients. Haematologica 2013, 98:1821-1825.
25. Fischbach M.A. Combination therapies for combating antimicrobial resistance. Curr Opin Microbiol 2011, 14:519-523.
26. Leclercq R., Canton R., Brown D.F., Giske C.G., Heisig P., MacGowan A.P., et al. EUCAST expert rules in antimicrobial susceptibility testing. Clin Microbiol Infect 2013, 19:141-160.
27. Kahlmeter G., Brown D.F., Goldstein F.W., MacGowan A.P., Mouton J.W., Osterlund A., et al. European harmonization of MIC breakpoints for antimicrobial susceptibility testing of bacteria. JAntimicrob Chemother 2003, 52:145-148.
28. Croxatto A., Prod'hom G., Greub G. Applications of MALDI-TOF mass spectrometry in clinical diagnostic microbiology. FEMS Microbiol Rev 2012, 36:380-407.
29. Frima H.J., Gabellieri C., Nilsson M.I. Drug delivery research in the European Union's Seventh Framework Programme for Research. JControl Release 2012, 161:409-415.
30. Pelgrift R.Y., Friedman A.J. Nanotechnology as a therapeutic tool tocombat microbial resistance. Adv Drug Deliv Rev 2013, 65:1803-1815.
31. So A.D., Gupta N., Brahmachari S.K., Chopra I., Munos B., Nathan C., et al. Towards new business models for R&D for novel antibiotics. Drug Resist Updat 2011, 14:88-94.
32. Boucher H.W., Talbot G.H., Benjamin D.K., Bradley J., Guidos R.J., Jones R.N., et al. 10× '20 Progress-development of new drugs active against Gram-negative bacilli: an update from the Infectious Diseases Society of America. Clin Infect Dis 2013, 56:1685-1694.
33. European Centre for Disease Prevention and Control (ECDC), European Medicines Agency (EMEA) Technical report 2009, The bacterial challenge: time to react, Available at:, [accessed 8.5.15]. http://www.ema.europa.eu/docs/en_GB/document_library/Report/2009/11/WC500008770.pdf.
34. Walsh C.T., Wencewicz T.A. Prospects for new antibiotics: a molecule-centered perspective. JAntibiot (Tokyo) 2014, 67:7-22.
35. Goemaere E., Melet A., Larue V., Lieutaud A., Alves de Sousa R., Chevalier J., et al. New peptide deformylase inhibitors and cooperative interaction: a combination to improve antibacterial activity. JAntimicrob Chemother 2012, 67:1392-1400.
36. Singh S.B., Young K., Miesel L. Screening strategies for discovery of antibacterial natural products. Expert Rev Anti Infect Ther 2011, 9:589-613.
37. Waldor M.K. Disarming pathogens-a new approach for antibiotic development. NEngl J Med 2006, 354:296-297.
38. Pastagia M., Schuch R., Fischetti V.A., Huang D.B. Lysins: the arrival of pathogen-directed anti-infectives. JMed Microbiol 2013, 62:1506-1516.
39. Bragg R., van der Westhuizen W., Lee J.Y., Coetsee E., Boucher C. Bacteriophages as potential treatment option for antibiotic resistant bacteria. Adv Exp Med Biol 2014, 807:97-110.
40. OXA-24/40 carbapenemase gene and the genes encoding the AbkA/AbkB proteins of a toxin/antitoxin system. JAntimicrob Chemother 2014, 69:2629-2633.